Home › Macular Degeneration › NCT07587515
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Who can join
Ages 50 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: * Known hypersensitivity or known allergy that would preclude study drug administration * Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access * Uncontrolled diabetes mellitus * History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit * Renal failure, dialysis, or history of renal transplant * Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion * Pregnant or breastfeeding women
About the study
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
What is being tested
- EYC-0305 (biological)
Sponsor: Eyconis INC. · Participants: 30 · Started: May 19, 2026
Contact the study team
- Kim Reed, OD, FAAO · Phone: 1-866-392-6647
- Karen Chu, MS · Phone: 1-866-392-6647
Official record on ClinicalTrials.gov — NCT07587515
Locations in the U.S.
| California | Beverly Hills, CA, Beverly Hills |
| North Carolina | Wake Forest, NC, Wake Forest |
| Pennsylvania | Erie, PA, Erie |
| Texas | Bellaire, TX, Bellaire McAllen, TX, McAllen The Woodlands, TX, The Woodlands |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.